2021OlympiABRCA1/2 adjuvantIn 1,836 patients with HER2-negative, high-risk early breast cancer and germline BRCA1/2 mutation, one year of adjuvant olaparib reduced invasive disease-free survival events compared with placebo.
2020KEYNOTE-522TNBC neoadjuvantIn 1,174 patients with stage II–III triple-negative breast cancer, neoadjuvant pembrolizumab + platinum/taxane → AC, then adjuvant pembrolizumab improved pathologic complete response and event-free survival compared with placebo + chemotherapy.
2020monarchEHR+/HER2– adjuvantIn 5,637 patients with HR+/HER2– node-positive high-risk early breast cancer, two years of abemaciclib added to endocrine therapy reduced invasive disease-free survival events compared with endocrine therapy alone.
2019KATHERINEHER2+ residual diseaseIn 1,486 patients with HER2+ early breast cancer and residual invasive disease after neoadjuvant taxane + trastuzumab, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease-free survival events compared with trastuzumab.
2012CLEOPATRAHER2+ metastaticIn 808 patients with HER2-positive metastatic breast cancer, first line, pertuzumab + trastuzumab + docetaxel improved progression-free and overall survival compared with placebo + trastuzumab + docetaxel.